TMCnet News
BeiGene to Present Clinical Data on PARP Inhibitor Pamiparib at Annual Scientific Meeting and Education Day of the Society for Neuro-OncologyCAMBRIDGE, Mass. and BEIJING, China, Nov. 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced it will present data on its investigational PARP inhibitor pamiparib at the 23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), being held November 15-18 in New Orleans, LA. Discovered by BeiGene, pamiparib is currently in global clinical development as a monotherapy and in combination with other agents for a variety of solid tumor malignancies. Oral Presentation:
Pamiparib (BGB-290) is an investigational inhibitor of PARP1 and PARP2 which has demonstrated pharmacological properties such as brain penetration and PARP-DNA complex trapping in preclinical models. Discovered by BeiGene scientists in Beijing, pamiparib is currently in global clinical development as a monotherapy and in combination with other agents for a variety of solid tumor malignancies. About BeiGene Investor Contact Media Contact 1ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation. |